CMG
51
-2
BEN
48
2
NRG
52
-8
FTI
79
-3
STX
66
4
MAS
58
-4
DIS
70
10
LMT
50
3
SLG
39
9
DE
45
-3
BXP
39
-2
DVA
49
2
BA
40
-2
PFG
67
2
CA
21
6
HPQ
49
-10
WY
39
2
CME
45
-3
INTU
65
5
PRU
76
14
CMG
51
-2
BEN
48
2
NRG
52
-8
FTI
79
-3
STX
66
4
MAS
58
-4
DIS
70
10
LMT
50
3
SLG
39
9
DE
45
-3
BXP
39
-2
DVA
49
2
BA
40
-2
PFG
67
2
CA
21
6
HPQ
49
-10
WY
39
2
CME
45
-3
INTU
65
5
PRU
76
14
Financhill
Back

Trevi Therapeutics, Inc. 10K Form

Buy
61

TRVI
Trevi Therapeutics, Inc.

Last Price:
$13.47
Seasonality Move:
49.5%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TRVI News And Ratings

See the #1 stock for the next 7 days that we like better than TRVI

TRVI Financial Statistics

Sales & Book Value

Annual Sales: $0
Cash Flow: $-10.9M
Price / Cash Flow: 0
Annual Sales: $1.48
Price / Book: 9.1

Profitability

EPS (TTM): -0.37130
Net Income (TTM): $-45.9M
Gross Margin: $-147K
Return on Equity: -35.48%
Return on Assets: -33.02%

Trevi Therapeutics, Inc. Earnings Forecast

Key Trevi Therapeutics, Inc. Financial Ratios

  • Per Share Earnings over the last 9 years have been positive in 4 years.

Trevi Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: TRVI
CUSIP: 89532M
Website: trevitherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 21.93
Quick Ratio: 21.56

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

TRVI Technical Analysis vs Fundamental Analysis

Buy
61
Trevi Therapeutics, Inc. (TRVI) is a Buy

Is Trevi Therapeutics, Inc. a Buy or a Sell?